lexi
IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 67 
Small font sizeDefault font sizeIncrease font size
Read this article

 


    Article Cited by others

RESEARCH ARTICLE

Nature of action of sitagliptin, the dipeptidyl peptidase-IV inhibitor in diabetic animals

Davis Joseph A, Singh Shuchita, Sethi Sachin, Roy Subhasis, Mittra Shivani, Rayasam Geetavani, Bansal Vinay, Sattigeri Jitendra, Ray Abhijit

Year : 2010| Volume: 42| Issue : 4 | Page no: 229-233

   This article has been cited by
 
1 Stability of extemporaneously prepared sitagliptin phosphate solution
Abdel Naser Zaid, Yara Abu Zaaror, Aiman Kaddumi, Mashhour Ghanem, Nidal Jaradat, Tharaa Abu Salah, Sameera Siaj, Lana Omari, Girish Sailor
PLOS ONE. 2022; 17(3): e0262068
[Pubmed]  [Google Scholar] [DOI]
2 Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease
Simone E. Jaenisch, Catherine A. Abbott, Mark D. Gorrell, Peter Bampton, Ross N. Butler, Roger Yazbeck
Clinical and Translational Gastroenterology. 2022; 13(1): e00452
[Pubmed]  [Google Scholar] [DOI]
3 Synthesis, Characterization and Screening of Some Novel 2-Methyl-N'- [(Z)-Substituted-Phenyl ethylidene] Imidazo [1, 2-a] Pyridine-3-Carbohy drazide Derivatives as DPP-IV Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Prerana A. Chavan, Shailaja B. Jadhav
Letters in Drug Design & Discovery. 2022; 19(2): 160
[Pubmed]  [Google Scholar] [DOI]
4 HL-7 and HL-10 Peptides Stimulate Insulin Secretion in the INS-1 Insulinoma Cell Line through Incretin-Dependent Pathway and Increasing the Glucose Uptake in L6 Myoblast
Zahra Setayesh-Mehr, Mahdiye Poorsargol
International Journal of Peptide Research and Therapeutics. 2021; 27(4): 2231
[Pubmed]  [Google Scholar] [DOI]
5 Sitagliptin relieves diabetic nephropathy fibrosis via the MAPK/ERK signaling pathway
Shufeng Cheng, Liang Li, Chunquan Song, Huijing Jin, Shouguo Ma, Ping Kang
Minerva Endocrinologica. 2020; 45(3)
[Pubmed]  [Google Scholar] [DOI]
6 CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function
A.G. McCloskey, M.G. Miskelly, C.B.T. Moore, M.A. Nesbit, K.A. Christie, A.I. Owolabi, P.R. Flatt, A.M. McKillop
Peptides. 2020; 125: 170251
[Pubmed]  [Google Scholar] [DOI]
7 Alkaloid Fraction of Litsea glutinosa Leaves Provides an Important Precursor for Inhibition of Dipeptidyl Peptidase 4 Activity
S W Kisnawaty, P Nityasewaka, B A R Sukma, A V Putrinadia, T Ma’rifah, D G Tamtomo, D Indarto
IOP Conference Series: Materials Science and Engineering. 2019; 546(6): 062013
[Pubmed]  [Google Scholar] [DOI]
8 The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease
Suncica Buljevic, Dijana Detel, Ester P. Pugel, Jadranka Varljen
Journal of Cellular Biochemistry. 2018; 119(8): 6743
[Pubmed]  [Google Scholar] [DOI]
9 Compare clinical efficacy between vildagliptin 100 mg and sitagliptin 100 mg in inadequate patients with sitagliptin 50 mg
Kuribayashi, N.
Therapeutic Research. 2012; 33(5): 703-710
[Pubmed]  [Google Scholar]
10 Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)
Masaya Sakamoto,Rimei Nishimura,Taiga Irako,Daisuke Tsujino,Kiyotaka Ando,Kazunori Utsunomiya
Cardiovascular Diabetology. 2012; 11(1): 92
[Pubmed]  [Google Scholar] [DOI]
11 Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
B. Ahrén,A. Schweizer,S. Dejager,E. B. Villhauer,B. E. Dunning,J. E. Foley
Diabetes, Obesity and Metabolism. 2011; 13(9): 775
[Pubmed]  [Google Scholar] [DOI]
12 Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222
Robert J. Greene,Hua Tu,John P. Gibbs,J. Greg Slatter
Xenobiotica. 2011; 41(11): 945
[Pubmed]  [Google Scholar] [DOI]
13 Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice
P. Bansal,P. Paul,G. Shankar,D. Munjal,P.G. Nayak,K.I. Priyadarsini,M.K. Unnikrishnan
Biomedicine & Preventive Nutrition. 2011; 1(4): 268
[Pubmed]  [Google Scholar] [DOI]
14 Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222
Greene, R.J., Tu, H., Gibbs, J.P., Greg Slatter, J.
Xenobiotica. 2011; 41(11): 945-957
[Pubmed]  [Google Scholar]
15 Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice
Bansal, P., Paul, P., Shankar, G., Munjal, D., Nayak, P.G., Priyadarsini, K.I., Unnikrishnan, M.K.
Biomedicine and Preventive Nutrition. 2011; 1(4): 268-272
[Pubmed]  [Google Scholar]
16 Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E.B., Dunning, B.E., Foley, J.E.
Diabetes, Obesity and Metabolism. 2011; 13(9): 775-783
[Pubmed]  [Google Scholar]
17 Clinical experience of a selective dipeptidyl peptidase IV inhibitor, vildagliptin
Tomioka, Y.
Therapeutic Research. 2011; 32(6): 841-849
[Pubmed]  [Google Scholar]

 

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow